Explore the vast range of titles available.

Current in vitro models of 3D tumor spheroids within the microenvironment have emerged as promising tools for understanding tumor progression and potential drug responses. However, creating spheroids with functional vasculature remains challenging in a controlled and high‐throughput manner. Herein, a novel open 3D‐microarray platform is presented for a spheroid‐endothelium interaction (ODSEI) chip, capable of arraying more than 1000 spheroids on top of the vasculature, compartmentalized for single spheroid‐level analysis of drug resistance, and allows for the extraction of specific spheroids for further analysis. As proof of concept, the crosstalk between breast cancer spheroids and vasculature is monitored, validating the roles of endothelial cells in acquired tamoxifen resistance. Cancer spheroids exhibited reduced sensitivity to tamoxifen in the presence of vasculature. Further analysis through single‐cell RNA sequencing of extracted spheroids and protein arrays elucidated gene expression profiles and cytokines associated with acquired tamoxifen resistance, particularly involving the TNF‐α pathway via NF‐κB and mTOR signaling. By targeting the highly expressed cytokines (IL‐8, TIMP1) identified, tamoxifen resistance in cancer spheroid can be effectively reversed. In summary, the ODSEI chip allows to study spheroid and endothelial interaction in various contexts, leading to improved insights into tumor biology and therapeutic strategies. The ODSEI chip, a novel 3D‐microarray platform, co‐cultures tumor spheroids on the vasculature, enabling drug treatment and specific spheroid extraction. The ODSEI chip demonstrates reduced tamoxifen sensitivity within spheroids when interacting with endothelial cells. Single‐cell RNA sequencing and protein arrays identify gene expression profiles and cytokines associated with tamoxifen resistance while further targeting identified cytokines effectively reduced drug resistance.

Open Microfluidic Platform The cover features an innovative open microfluidic platform that enables direct culture and analysis of tumor spheroids interacting with blood vessels, developed by Yoon‐Kyoung Cho and co‐workers. The image showcases the high‐throughput chip where cancer spheroids (detailed in circular inset) can be grown and retrieved for genetic analysis while studying their interactions with the underlying vasculature, advancing our understanding of tumor drug resistance mechanisms. More details can be found in article number 2410659.

Background Cystoid macular oedema (CMO) is an uncommon complication associated with hydroxychloroquine (HCQ) retinopathy threatening central vision. We report a patient with HCQ retinopathy and CMO, for which an intravitreal dexamethasone implant was used, which led to complete resolution of oedema. Case presentation A 57-year-old woman with systemic lupus erythematosus (SLE) complaining of blurred vision in both eyes was diagnosed with bilateral HCQ retinopathy and CMO based on characteristic photoreceptor defects and cystoid spaces on optical coherence tomography, hypo-autofluorescence on fundus autofluorescence, and corresponding visual field defects. After treatment with systemic acetazolamide and topical dorzolamide, CMO showed partial resolution in the right eye. Owing to worsening renal function, an intravitreal dexamethasone implant was placed in the right eye, which resulted in resolution of CMO and visual improvement from 20/50 to 20/30. Conclusion Intravitreal dexamethasone implant may be effective for the treatment of CMO in HCQ retinopathy, particularly for the cases refractory to systemic or topical carbonic anhydrase inhibitors.

In this work, we present Facial Identity Controllable GAN (FICGAN) for not only generating high-quality de-identified face images with ensured privacy protection, but also detailed controllability on attribute preservation for enhanced data utility. We tackle the less-explored yet desired functionality in face de-identification based on the two factors. First, we focus on the challenging issue to obtain a high level of privacy protection in the de-identification task while uncompromising the image quality. Second, we analyze the facial attributes related to identity and non-identity and explore the trade-off between the degree of face de-identification and preservation of the source attributes for enhanced data utility. Based on the analysis, we develop Facial Identity Controllable GAN (FICGAN), an autoencoder-based conditional generative model that learns to disentangle the identity attributes from non-identity attributes on a face image. By applying the manifold k-same algorithm to satisfy k-anonymity for strengthened security, our method achieves enhanced privacy protection in de-identified face images. Numerous experiments demonstrate that our model outperforms others in various scenarios of face de-identification.

A new experiment, which is called as NEOS (NEutrino Oscillation at Short baseline), is proposed on the site of Hanbit reactors at Yonggwang, South Korea, to investigate a reactor antineutrino anomaly. A homogeneous NEOS detector having a 1000-L target volume has been constructed and deployed at the tendon gallery ~25 m away from the reactor core. A linear alkylbenzene (LAB) is used as a main base solvent of the NEOS detector. Furthermore, a di-isopropylnaphthalene (DIN) is added to improve the light output and pulse shape discrimination (PSD) ability. The ratio of LAB to DIN is 90:10. PPO (3 g/L) and bis-MSB (30 mg/L) are dissolved to formulate the mixture of LAB- and DIN-based liquid scintillator (LS). Then, ~0.5% gadolinium (Gd) is loaded into the LS by using the solvent-solvent extraction technique. In this paper, we report the characteristics of Gd-loaded LS (GdLS) for the NEOS detector and the handling during mass production.